Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3S-002 Monotherapy or Combination Therapy in Advanced Solid Tumors With MAPK Pathway Mutations
NCT05886920Phase 2Recruiting
- Sponsor
- D3 Bio
- Start
- Jul 2023
- Primary completion
- Aug 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 4
01
Overview
Phase 2, open-label trial of D3S-002 in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by D3 Bio. Primary endpoints: Number of Participants With Adverse Events, Maximum Tolerated Dose up to 24 months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
D3S-002
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05886920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886920.